A detailed history of Efg Asset Management (North America) Corp. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 75,748 shares of ACAD stock, worth $1.12 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
75,748
Previous 75,384 0.48%
Holding current value
$1.12 Million
Previous $1.39 Million 11.7%
% of portfolio
0.22%
Previous 0.25%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$14.62 - $18.42 $5,321 - $6,704
364 Added 0.48%
75,748 $1.23 Million
Q1 2024

May 13, 2024

BUY
$17.79 - $30.86 $505,324 - $876,578
28,405 Added 60.46%
75,384 $1.39 Million
Q4 2023

Feb 08, 2024

BUY
$20.78 - $31.77 $147,496 - $225,503
7,098 Added 17.8%
46,979 $1.47 Million
Q3 2023

Nov 02, 2023

BUY
$20.84 - $33.47 $831,120 - $1.33 Million
39,881 New
39,881 $831,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.